ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Christian Kähler contributed 18 entries already.
Through a new partnership with VWR, TriLink Biotechnologies has made its catalogue of industry-leading nucleic acid technologies more available in Europe. By improving the ordering process and reducing lead times, this partnership will support early-phase researchers and established commercial clients with cutting-edge mRNA products.
High-Quality HIV Antigens for Cutting-Edge Solutions
Customized Enzymes and Reagents from New England Biolabs
Neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) suffer from a scarcity of effective treatments. Current therapies primarily provide symptomatic relief but do not address the underlying pathology, failing to slow or halt disease progression. This underscores the urgent need to identify new therapeutic targets relevant to the pathology of these conditions. Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely unexplored, presenting a promising avenue for future research and therapeutic development.
Dunn Labortechnik presents the new TEERZ device from Applied BioPhysics.
We are witnessing a significant industrial transformation driven by the adoption of digital tools to manage increasing data volumes and automation to streamline workflows. However, inefficiencies in process development and data management continue to pose major challenges. These challenges are magnified by the complexities of scaling biologics production and ensuring consistency across global teams. Digital tools present an opportunity to improve efficiency and enable remote monitoring of your bioreactor cultures. Introducing BioNsight cloud, a true cloud-based software solution for bioprocess monitoring and analysis. It is fully integrated into the Eppendorf bioprocess control software DASware® control 6 and also features DataHowLab, an innovative AI-enabled analytics solution to save time and resources during process development.
Medix Biochemica expands its offering of critical in vitro diagnostics (IVD) raw materials to premium blockers and stabilizers by acquiring CANDOR Bioscience.
Lille hosted the 2024 editions of BioFIT, MedFIT, and MEDigIT, three internationally recognised events dedicated to innovation in Life Sciences, MedTech and Digital Health. These gatherings serve as catalysts for collaboration and progress, each focusing on a specific aspect of the healthcare innovation landscape.
Jena-based InflaRx has reached a significant milestone with the European Commission’s approval of GOHIBIC (Vilobelimab), a novel anti-C5a monoclonal antibody for the treatment of SARS-CoV-2-induced Acute Respiratory Distress Syndrome (ARDS).
The Paul Ehrlich Institute (PEI) has approved expansion of the global INVISE Phase 1 clinical trial to Europe. The study aims to evaluate first-in-class gene therapy for the treatment of B-cell malignancies.